Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive...

Area of Science:

• Cardiology
• Molecular Biology
• Genetics

Background:

• Left ventricular hypertrophy is a primary risk factor for heart failure.
• Traditional views consider myocardial hypertrophy a compensatory response to increased workload.
• Recent research suggests distinct compensatory and maladaptive forms of hypertrophy exist.

Purpose of the Study:

• To review characteristics associated with heart failure development in animal and clinical studies.
• To explore molecular pathways distinguishing beneficial from maladaptive hypertrophy.
• To identify potential biological targets for human heart failure treatment.

Main Methods:

• Review of findings from experimental animal models.
• Analysis of clinical studies, including Framingham studies.
• Integration of molecular biology insights into hypertrophy concepts.

Main Results:

• Left ventricular hypertrophy is a key risk factor for heart failure.
• A novel concept distinguishes compensatory from maladaptive hypertrophy.
• Maladaptive hypertrophy, not compensatory, leads to cardiac failure.
• The role of hypertrophy in compensating for wall stress may be outdated.

Conclusions:

• Understanding the molecular basis of hypertrophy is crucial for heart failure treatment.
• Identifying pathways that differentiate beneficial from maladaptive hypertrophy offers therapeutic targets.
• Molecular insights are reshaping our understanding of cardiac hypertrophy and failure.